Skip to main content
. 2019 Jun 14;26(10):1207–1216. doi: 10.1177/1352458519855722

Table 1.

Patient demographics and baseline clinical characteristics according to BVL group for the ITT population with valid scan at Baseline and Year 2a.

Group 1
Least BVL (⩽0.52% reduction)
n = 221
Group 2
Intermediate BVL (>0.52%–2.18% reduction)
n = 357
Group 3
Most BVL (>2.18% reduction)
n = 131
Age, mean (SD), years 38.4 (8.0) 37.8 (8.8) 36.1 (9.3)
Female sex, no. (%) 152 (68.8) 272 (76.2) 99 (75.6)
Time since diagnosis of MS, mean (SD), years 5.2 (5.8) 5.3 (5.5)b 4.3 (4.8)
Time since first symptoms of MS, mean (SD), years 8.6 (7.2) 8.9 (7.0) 7.7 (6.5)
Time since most recent relapse onset, mean (SD), months 6.6 (3.4) 6.8 (3.7) 6.8 (4.0)
Relapses, mean (SD), no.
 In previous year 1.3 (0.7)c 1.3 (0.7)d 1.4 (0.7)e
 In previous 2 years 2.1 (0.9) 2.2 (0.9) 2.3 (1.0)
MS subtype, n (%)
 Relapsing remitting 204 (92.3) 336 (94.1) 122 (93.1)
Use of previous MS treatment in the last 2 years, n (%) 47 (21.3) 83 (23.2) 35 (26.7)
Baseline EDSS score, mean (SD) 2.4 (1.2) 2.5 (1.3) 2.8 (1.3)
Number of contrast-enhancing lesions, mean (SD) 0.5 (1.2)f 1.2 (2.8) 4.0 (7.9)
Baseline normalized brain volume, cm3, mean (SD) 1514.6 (74.8) 1509.5 (77.7) 1476.3 (85.1)
Baseline T2-weighted lesion volume, mL, mean (SD) 10.1 (11.1) 14.8 (14.8) 25.5 (17.7)

BVL: brain volume loss; EDSS: Expanded Disability Status Scale; ITT: intent-to-treat; SD: standard deviation.

a

The ITT population represents pooled data from placebo and active treatment groups.

b

n = 356.

c

n = 172.

d

n = 277.

e

n = 103.

f

n = 220.